Press
Press inquiries: press@nightboxllc.com
One-line description
Nightbox LLC is a Wyoming-incorporated, LA-area gene therapy startup developing a chimeric NKG2D-LIF6 construct that encodes the elephant cancer-resistance gene into a tumor-only trigger.
Factsheet
| Founded | February 2026 |
| Headquarters | Wyoming (incorporated) · Los Angeles area (operations) |
| Founder & CEO | Artem Shakin |
| Industry | Biotechnology · Gene Therapy |
| Stage | Pre-seed |
| Lead asset | NKG2D-LIF6 chimeric receptor-effector (2,123 bp) |
| Indication | Solid tumor oncology (CRC, melanoma, pancreatic — initial) |
| Modality | AAV9-delivered single-construct gene therapy |
| EIN | 39-4373044 |
Story angles
- Solo-founder biotech using AI agent infrastructure as core R&D — modern minimalist company structure
- Comparative cancer biology applied directly: encoding the elephant LIF6 mechanism into a therapeutic
- Bypassing CAR-T manufacturing bottleneck via single-construct gene therapy
- Clean IP whitespace on the specific NKG2D-LIF6 chimera (no prior art on the combination)
- Wyoming legal structure plus Los Angeles area operations — emerging hub outside Boston/Bay Area
Quotes available
Artem Shakin (Founder & CEO) is available for interviews on cancer biology, comparative oncology, AI-augmented biotech operations, and the NKG2D-LIF6 platform. Contact: press@nightboxllc.com.